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Abstract
Pulmonary arterial hypertension is an unmet clinical need. Imatinib, a tyrosine kinase inhibitor, 200 to 400mg daily reduces
pulmonary artery pressure and increases functional capacity in this patient group, but is generally poorly tolerated at the
higher dose. We have designed an open-label, single-arm clinical study to investigate whether there is a tolerated dose of imatinib
that can be better targeted to patients who will benefit. The study consists of two parts. Part 1 seeks to identify the best tolerated
dose of Imatinib in the range from 100 and up to 400mg using a Bayesian Continuous Reassessment Method. Part 2 will measure
efficacy after 24 weeks treatment with the best tolerated dose using a Simon’s two-stage design. The primary efficacy endpoint is a
binary variable. For patients with a baseline pulmonary vascular resistance (PVR) >1000 dynes  s  cm5, success is defined by an
absolute reduction in PVR of 300 dynes  s  cm5 at 24 weeks. For patients with a baseline PVR 1000 dynes  s  cm5, success is
a 30% reduction in PVR at 24 weeks. PVR will also be evaluated as a continuous variable by genotype as an exploratory analysis.
Evaluating the response to that dose by genotype may inform a prospective biomarker-driven study.
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Background and rationale
Pulmonary arterial hypertension (PAH) is an uncommon
condition characterised by pre-capillary resistance to pul-
monary blood flow in the absence of airway or parenchymal
lung diseases, left heart failure or chronic thromboembo-
lism.1–3 In around 50% of patients, there is no identifiable
underlying cause and patients are classified as idiopathic
PAH or, where there is a family history, heritable PAH.
Histological examination of post-mortem or transplanta-
tion PAH lung tissue shows marked pulmonary arterial
remodelling with vascular cell proliferation narrowing the
vascular lumen.4
PAH is an unmet clinical need. Five-year mortality for
idiopathic/heritable PAH managed by experienced centres
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in the UK is around 58% and long-term survival when
associated with co-morbidities, such as connective tissue
disease, is worse.5 The current licensed treatments (prosta-
noids, endothelin receptor antagonists, phosphodiesterase
type 5 inhibitors and soluble guanylate cyclase stimulator)
focus on pharmacologically manipulating three signalling
pathways recognised for regulating vascular tone.1–3 These
treatments have little impact on the underlying vascular
remodelling4 and do not arrest or reverse the course of
the condition.
The past decade has seen attempts to target other signal-
ling pathways using drugs with pronounced antiprolifera-
tive or anti-inflammatory properties.3,6 One such drug is
Imatinib, an orally active tyrosine kinase inhibitor.7–10
Imatinib inhibits platelet-derived growth factor receptor
(PDGFR) alpha and beta, BCR-ABL, discoidin domain
receptor (DDR) and c-KIT.11 Studies of lung tissue from
PAH patients show increased PDGF activity and c-KIT
expression associated with remodelled vessels.12,13
PDGF is a potent vascular smooth muscle cell mitogen,14
while c-kit is a marked of bone marrow–derived hematopoi-
etic stem cells.13 Imatinib reverses pulmonary hypertension
in experimental models.7 This is consistent with the antipro-
liferative properties of Imatinib, but it has also been
reported that Imatinib can reduce pulmonary vascular
tone.15–17
The most robust human data come from two placebo-
controlled randomised clinical trials: a Phase II trial involv-
ing 59 patients9 and a Phase III trial (IMPRES) including
202 patients10 taking Imatinib 200 to 400mg daily. The
phase II study showed a significant decrease in pulmonary
vascular resistance (PVR) compared to a placebo and
IMPRES10 reported a significant improvement at
24 weeks in functional capacity, with a mean placebo-
corrected treatment effect on six-minute walk distance
(6MWD) of 32 m (95% confidence interval, 12–52;
p¼ 0.002), and in PVR of –379 dyne  s  cm–5 (95% confi-
dence interval, –502 to –255; p<0.001) in patients taking
Imatinib along with their licensed vasodilatory treat-
ments.10 Unfortunately, serious adverse events and discon-
tinuations were more common in the Imatinib group10 and
the FDA requested further safety data. The drug remains
unlicensed for PAH.
Despite these concerns, and in the absence of alternative
effective treatments, there remains considerable interest in
the use of Imatinib for PAH, administered orally or by
inhalation.18–20 Imatinib is established as a treatment for
chronic myeloid leukaemia21 and gastro-intestinal stromal
tumour.22 Imatinib is used occasionally in refractory PAH
on compassionate grounds, but usually in doses lower than
400mg, a dose used frequently in oncology. To address the
previous safety concerns, and before moving on to an effi-
cacy study, there is a need to establish a dose of Imatinib
that is best tolerated by patients with PAH.
In positioning Imatinib for PAH, attention must also be
given to inter-individual variability in response, seen with
most drugs and evident with Imatinib.10 Where there are
safety considerations, there is benefit in exploring if
Imatinib can be better targeted at patients more likely to
respond and reduce exposure to those least likely to benefit.
Trough plasma levels are known to vary, influenced among
other factors by substrates, inhibitors and inducers of
CYP3A4.23 Variation in drug target expression and func-
tion may also be factors. For example, haematological
malignancies driven by somatic PDGFRB mutations are
very sensitive to Imatinib.24,25 Of note here, three separate
population-based studies have identified a cis-acting protein
quantitative trait locus (pQTL) located close to PDGFRB,
influencing circulating levels of PDGFRB, that reaches
genome-wide significance.26–28 If PDGFRB is an important
target for Imatinib in PAH, common genetic variants
influencing PDGFRB protein levels may affect therapeutic
response, or at least the dose required to elicit a response,
and the risk of dose-limiting adverse effects.
Here we detail the protocol for an adaptive clinical trial
directed at identifying the best tolerated dose of Imatinib in
PAH patients (Part 1) and discuss options for investigating
the efficacy of that dose in a seamless follow-on study
(Part 2), exploring response according to genotype. The
protocol has been approved by the NHS Health Research
Authority (IRAS PROJECT ID 274093, REC Reference
20/SC/0240).
Objectives
The study has two main objectives, each studied in two
distinct parts.
Primary
Part 1: To identify the best tolerated dose of Imatinib
(between 100mg and 400mg once daily for a target treat-
ment duration of at least four weeks) in patients with PAH.
Part 2: To assess the efficacy of Imatinib administered at the
best tolerated dose as identified in Part 1 (when taken once
daily for 24 weeks) on PVR in PAH.
Secondary
1. To analyse the change in PVR at 24 weeks according to
genes that influence the actions of PDGF.
2. To identify plasma proteins and genetic variants that pre-
dict the clinical response to Imatinib.
3. To identify plasma proteins that report an early thera-
peutic response to Imatinib.
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Methods
Overview
Part 1 follows a single-dose escalation protocol. We will
recruit a minimum of 6 and up to 13 patients to explore
four doses of Imatinib (100mg, 200mg, 300mg and 400mg
once daily) with the aim of recommending a best tolerated
dose using a Bayesian continual reassessment method
(CRM).29 We consider the best tolerated dose to be that
which has a 20% probability that a patient will not be
able to continue imatinib for five consecutive days and we
aim to identify the dose that is most likely to meet this
tolerability criterion. For the CRM model, tolerability will
be assessed after the first four weeks of treatment. Patients
will, however, be continued on their allocated dose for up to
24 weeks to assess safety beyond the four-week tolerability
evaluated by the CRM, with clinicians allowed to
modify the dose in that period according to clinical
need. This additional information on longer term tolerabil-
ity will not influence the dose recommended by the CRM
model for sequential patients in Part 1 but may be consid-
ered when making a final dose recommendation for Part 2
of the study.
Part 2 will measure the change in PVR from baseline
after 24 weeks of Imatinib at the best tolerated dose using
a Simon two-stage design.30 For the purpose of identifying
‘responders’, we define treatment response to be an absolute
reduction in PVR of 300 dynes  s  cm5 at 24 weeks for
patients with a baseline PVR >1000 dynes  s  cm5 and a
30% reduction in PVR at 24 weeks for patients with a base-
line PVR 1000 dynes  s  cm5. Define p as the true
response rate of the treatment. Our null hypothesis is H0:
p  p0¼ 0.1 and alternative hypothesis is H1: p> p0¼ 0.1.
We denote a the type-I error-rate, defined here the prob-
ability of rejecting the null hypothesis for a treatment that
has response rate p0. We define b as the type-II error-rate
and therefore 1–b as the power; here the probability of
rejecting the null hypothesis for a treatment that has
response rate p1. We choose p1¼ 0.27. We will choose a
design that has a type-I error-rate of a  0.05 and power
1–b  0.8, with a maximum sample size of 34. One suit-
able Simon design includes an interim analysis once 13
patients have completed 24 weeks of treatment on the
recommended best tolerated dose. If there are zero
responses or one response in these 13 patients, the study
will be stopped without rejecting the null hypothesis.
Otherwise, that is, if there are two or more responses,
additional patients will be recruited for a total of 34 evalu-
able patients. In such a design, the null hypothesis is
rejected if seven or more responses are observed in the
34 patient cohort. This design and its operating character-
istics are described in the statistics and data analysis plan
section.
Study population
The study will recruit patients with symptomatic PAH.
A documented diagnosis of PAH by right heart
catheterisation is required prior to screening with evidence
of a resting mean pulmonary artery pressure 25mmHg,
pulmonary capillary wedge pressure 15mmHg, PVR >400
dynes  s  cm–5 (>5 wood units) and normal or reduced car-
diac output. Brain imaging is required at baseline to exclude
prior clinically significant cerebral haemorrhage. The inclu-
sion and exclusion criteria are given in Table 1. Patients will
be recruited from specialist centres recognised for their
expertise in the management of PAH (e.g., https://digital.
nhs.uk/data-and-information/clinical-audits-and-registries/
national-pulmonary-hypertension-audit#audit-reports) and
the UK PAH cohort study (https://ipahcohort.com).
Given the low prevalence of PAH, conducting a trial of
this size for this condition without this support would be
challenging.
Some patients with PAH who meet the entry criteria
will have implanted FDA/CE-approved pulmonary artery
pressure monitors (CardioMEMSTM) and cardiac rhythm
monitors that capture and relay cardiopulmonary
haemodynamics as well as daily activity to their local
hospital. These patients also have a remote monitoring
system to capture daily blood pressure, oxygen saturations
and body weight. This permits regular monitoring at
home. By including some patients with CardioMEMSTM
in Part 1 of this study we expect to obtain additional data
on the effect of Imatinib to support safety monitoring, the
timing and magnitude of any change in pulmonary hae-
modynamics and the relationship of plasma Imatinib levels
to pulmonary haemodynamics that could inform the
design of Part 2 of this study. We will present baseline
characteristics and results of this subgroup of participants,
without formal hypothesis testing, to explore any
differences between instrumented and non-instrumented
patients.
Investigational product
Imatinib mesilate 100mg or 400mg tablets.
Outcome measures and data collection
A tabulated summary of all visits and assessments is pro-
vided in Appendix 1.
Primary outcome measure
Part 1: Discontinuation of the drug for more than five con-
secutive days due to Grade 2 or above Adverse Events
defined by the National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (version 5.0,
2017), adapted for this study. For example, if a patient
experiences an adverse event and stops taking the study
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drug for two days but recovers and completes the four-week
treatment after the treatment break, the dose will be con-
sidered tolerable. However, if the treatment break is longer
than five days the dose will be considered intolerable. In all
cases, all adverse events will be recorded and reported irre-
spective if treatment is tolerated.
Part 2: The primary efficacy endpoint is a binary vari-
able. For patients with a baseline PVR >1000
dynes  s  cm5, an absolute reduction in PVR of 300
dynes  s  cm5 at 24 weeks is clinically meaningful. This
was the mean reduction recorded in the Phase II Imatinib
study in which the baseline PVR was 1124 dynes  s  cm5.9
Given that this absolute change is a substantial fall in PVR
for patients with a baseline below 1000 dynes  s  cm5,9
for these patients, proportionate success is a 30% reduction
in PVR at 24 weeks.31,32 Fig. 1 demonstrates how this trans-
lates into an equally meaningful reduction in PVR relative
to baseline.
Table 1. Summary of entry criteria.
Inclusion criteria:
1. Subjects aged between 18 and 80 years old.
2. PAH which is idiopathic, heritable, associated with connective tissue disease, PAH after  1 year repair of congenital systemic to pulmonary
shunt, or PAH associated with anorexigens or other drug.
3. Subjects willing to be genotyped for genes that influence PDGF activity.
4. Resting mean pulmonary artery pressure 25mmHg, pulmonary capillary wedge pressure 15mmHg, PVR> 400 dynes  s  cm5 (5 wood
units), and normal or reduced cardiac output.
5. Six-minute walking distance >50m at entry.
6. Stable on an unchanged PAH therapeutic regime comprising at least 2 therapies licensed for PAH (any combination of endothelin receptor
antagonist, phosphodiesterase inhibitor or prostacyclin analogue) for at least one month prior to screening.
7. Able to provide written informed consent prior to any study mandated procedures.
8. Contraception: Fertile females (women of childbearing potential) are eligible to participate after a negative highly sensitive pregnancy test, if
they are taking a highly effective method of contraception during treatment and until the end of relevant systemic exposure. Fertile males who
make use of condom and contraception methods during treatment and until the end of relevant systemic exposure in women of childbearing
potential.
Exclusion criteria:
1. Unable to provide informed consent and/or are non-fluent speakers of the English language.
2. Hypersensitivity to Imatinib or to any of the excipients.
3. Clinically-significant renal disease (confirmed by creatinine clearance <30ml/min per 1.73m2).
4. Clinically-significant liver disease (confirmed by serum transaminases >3 times than upper normal limit).
5. Patients receiving oral and/or parenteral anticoagulants.a
6. Anaemia confirmed by haemoglobin concentration <10 g/dl.
7. History of thrombocytopenia.
8. Individuals known to have haemoglobinopathy sickle cell disease, thalassaemia.
9. Hospital admission related to PAH or change in PAH therapy within 3 months prior to screening.
10. History of left-sided heart disease and/or clinically significant cardiac disease, including but not limited to any of the following:
a. Aortic or mitral valve disease (stenosis or regurgitation) defined as greater than mild aortic insufficiency, mild aortic stenosis, mild mitral
stenosis, moderate mitral regurgitation.
b. Mechanical or bioprosthetic cardiac valve.
c. Pericardial constriction, effusion with tamponade physiology, or abnormal left atrial size.
d. Restrictive or congestive cardiomyopathy.
e. Left ventricular ejection fraction 50% (measured in echocardiogram at screening).
f. Symptomatic coronary disease.
g. Significant (2þ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation.
h. Acutely decompensated left heart failure within 1 month of screening
i. History of untreated obstructive sleep apnoea
11. Evidence of significant lung disease on high-resolution CT (if available) or recent (performed within 12 months) lung function, where
FEV1< 50% predicted and FVC< 70% predicted, and DLCO (or TLCO)< 50% predicted if any CT abnormalities; judged by the Site
Physician.
12. Patients with a history of uncontrolled systemic hypertension.
13. Acute infection (including eye, dental, and skin infections).
14. Chronic inflammatory disease including HIV, and Hepatitis B.
15. Women of childbearing potential who are pregnant or breastfeeding (if applicable).
16. Previous intracerebral haemorrhage.
17. Patients who have received an Investigational Medicinal Product (IMP) within 5 half-lives of the last dose of the IMP or one month (whichever
is greater) before the b.
aThis does not apply to single antiplatelet therapy.
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Secondary measures
These comprise change from baseline to 24 weeks in (a)
6MWD from baseline, a measure of functional capacity,
(b) right ventricular ejection fraction by echocardiogram,
(c) plasma NT-proBNP levels, (d) quality of life score and
(e) PVR according to genes that regulate PDGF activity.
Exploratory outcome measures
Blood samples will be taken for Imatinib levels for pharma-
cokinetic analysis and for proteomic analysis.
Pharmacokinetic data will be analysed with respect to tol-
erability and pharmacodynamic response. Plasma protein
levels will be investigated for a profile that predicts response
to Imatinib and/or provides an early (four week post-
starting the drug) signal predicting response.
Statistics and data analysis plan
In Part 1, the dose selection of Imatinib for patients will be
guided using a Bayesian CRM, allowing us to include pre-
vious experience with the study drug to best understand
tolerability in an efficient and sequential manner. An initial
dose/toxicity skeleton was generated based on a one-
parameter power model in the form, p(tox|d)¼ da, where d
is the standardised dose and our single parameter a follows
a gamma (1,1) distribution. Taken together with our prior
belief of toxicities based on expert opinion and data from
the IMPRES trial,10 we built our initial skeleton dose tox-
icity curve (Fig. 2).
Patients will be recruited into the trial sequentially; the
first patient will receive the lowest dose of Imatinib (pro-
posed starting dose of 100mg). The best tolerated dose will
be re-estimated after each patient completes the four-week
follow-up, or earlier if a patient experiences an intolerable
response prior to the four-week follow-up, and this will be
recommended as the dose for the subsequent patient.
The dose escalation scheme is limited to a single 100mg
dose change with no dose skipping. A safety stopping rule
has also been imposed where, if the model identifies with
90% certainty that the lowest dose has a higher non-
Fig. 1. Change in pulmonary vascular resistance (PVR) relative to
baseline based on % and absolute values. Above a baseline of 1000
dynes, an absolute reduction of 300 dynes is clinically meaningful, while
with a baseline of 1000 dynes and below, a 30% reduction in PVR is
deemed to be clinically significant.
Fig. 2. (a) Prior dose non-tolerability skeleton with (b) prior guesses of probability of intolerable response.
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tolerability probability than the target non-tolerability level
(TNL) of 20%, the study will stop. The minimum and max-
imum number of patients to enter Part 1 of the trial will be 6
and 13, respectively. We included a lower bound of recruit-
ment at six patients to ensure that any intolerable responses
in the first patients do not trigger early termination without
adequate exploration of the doses. Under these constraints,
using simulation studies, we have explored the operating
characteristics of this trial design. If our prior tolerability
expectations hold true, a simulation study has shown the
trial design will correctly predict a dose within 10% of the
TNL 90% of the time (Fig. 3).
After the 13th patient completes follow-up, tolerability
and 90% credible intervals will be calculated for each dose
level to generate the dose/tolerability quotient based on our
four-week follow-up data and our prior understanding. We
aim to reach a precision of 20%. If it is not reached after the
first 13 patients, we are able to recruit further patients until
we reach a suitable level of precision. We will also report
Serious Adverse Events and toxicity incidence with or with-
out withdrawal from study.
The dose that will be recommended for Part 2 of the
study will be decided using the four-week tolerability data
derived using the CRM in Part 1, in conjunction with longer
term safety and efficacy data. As patients will continue their
allocated dose after their four -week treatment, the sequen-
tial nature of Part 1 will allow us to have access to long-term
safety data. In the best case at the point of the final patient
four-week follow-up, all other patients will have been on the
study drug for at least eight weeks. Using these data, we will
ensure that the longer term safety does not deviate from the
formally measured tolerability measured after four weeks.
This is an important validation step for Part 2 as the treat-
ment period is longer than Part 1. In the worst case that all
patients do not continue treatment after four weeks we will
recommend a dose based on the four-week data and any
potential efficacy data from the patients in Part 1 that have
implanted cardiac pressure instruments.
In Part 2, the efficacy of the best tolerated dose deter-
mined in Part 1 will be estimated in a single-arm, open-label
trial. The trial will contain at least one interim analysis, at
which point the trial may be stopped early for futility only
(freeing resources for other treatments of this rare condi-
tion). The trial will continue to recruit even if final trial
success is guaranteed, to enable data to be collected for
additional analyses. In particular, we would like to maxi-
mise the data obtained for the analysis of response by geno-
type. The required operating characteristics for the trial are
a type-I error-rate of 0.05 for a response rate p¼ p0¼ 0.10
and a power of 80% for a response rate p¼ p1¼ 0.27.
The simplest design approach for such a trial is a single-
stage trial, where a fixed number of participants, N, receive
the treatment. In a single-stage trial, success is declared if
the final number of responses, r, exceeds some specified
value. For the design parameters and required operating
characteristics of this trial, the smallest possible sample
size for a single-stage trial is N¼ 32. A popular alternative
to the single-stage design is the Simon design.30 The Simon
design is a two-stage design, meaning that there is an inter-
im analysis in addition to the final analysis. This interim
Fig. 3. Simulation results based on the trial design outlined in Part 1. (a) Simulated trial trajectories based on 2000 simulations and our prior
skeleton. (b) A table showing the average dose recommendations of 2000 simulations based on our prior understanding of tolerability being true.
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analysis takes place when some n1 results are available. At
this interim analysis, the number of responses is compared
to a specified value, r1. If the number of responses does not
exceed the specified interim value of r1, the trial will be
stopped with no further recruitment. Otherwise, the trial
continues to recruit until some maximum sample size, N,
is reached. The advantage of the Simon design over a single-
stage design is that when the treatment does not show prom-
ise, a decision is reached more quickly, without an increase
in type-I error-rate. Fig. 4 shows an example of a Simon
design that satisfies the required type-I error-rate and
power. In this trial, an interim analysis takes place after
n1¼ 13 results are available. At this point, the trial would
end with a ‘no go decision’ if the number of responses is less
than or equal to r1¼ 1. Otherwise, the trial continues until
all N¼ 34 results are available, at which point a ‘go deci-
sion’ would be made or trial success declared if the number
of responses observed is greater than r¼ 6. If the number of
responses observed is less than or equal to 6, a no-go deci-
sion would be made.
We have modelled other adaptive designs satisfying the
same operating characteristics. In the Simon design, early
stopping may only occur at the interim analysis, that is,
stopping is not permitted even when the final trial decision,
go or no go, is known with certainty. For example, this
would be the case in the above Simon design after 2
responses out of 30 results, at which point a no-go decision
is certain even if all remaining results are responses.
Stopping the study under this design when such certainty
exists is known as non-stochastic curtailment. It may be the
case that a go decision is extremely likely or extremely
unlikely, though not yet certain. For example, this is the
case in the above Simon design after 2 responses out of 29
results, where a go decision is still possible but unlikely even
if the treatment has the desired response rate. In this exam-
ple, 5 responses would be required from the 5 remaining
results in order to reach 7 responses in total (and thus a
go decision). Stopping a trial in such circumstances, when
a go decision is particularly likely or unlikely, is known as
stochastic curtailment. Permitting curtailment of either kind
in a trial design can result in a design with more appealing
properties than an equivalent Simon design. In particular,
designs using curtailment may be superior in terms of a
combination of the following three criteria: maximum
sample size N, expected sample size if response rate
p¼ p0¼ 0.1 (ESS(p0)), that is, if the treatment does not
work and expected sample size if response rate p¼ p1¼ 0.27
(ESS(p1)), that is, if the treatment works.
33,34 One example
of such a design is shown in Fig. 5.
Compared to the Simon design, the proposal in Fig. 5
has a smaller maximum sample size (33 vs. 34) and a smaller
expected sample size if the treatment works (27.7 vs. 32).
The expected sample size if the treatment does not work is
greater (22.4 vs. 21). There is one additional analysis; these
interim analyses would take place after 11 and 22 partici-
pants. Here, the trial would end early for lack of effect if
there are 0 responses at the first analysis or if there are fewer
than 3 responses at the second analysis. This trial would end
for a positive effect only if trial success by the end of
the trial was certain; that is, the number of responses is
greater than 6.
We have the option to change the design of Part 2 by
amendment. We will inform the decision on the design
by making use of tolerability and efficacy data collected in
Part I. We will undertake two sensitivity analyses for the
primary outcome in Part 2: we will compare response rates
between participants with PVR> 1000 dynes  s  cm5 and
PVR 1000 dynes  s  cm5 at baseline. We will also analyse
Fig. 4. Potential Simon design for Part 2.
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the change in PVR from baseline as a continuous outcome.
The design realisation used, that is, the specific set of inter-
im analysis points and corresponding stopping boundaries,
will be chosen before the beginning of Part 2. While incor-
porating, for example, non-stochastic curtailment for futil-
ity would be useful as it would improve the operating
characteristics of the trial, stopping this trial has to be
weighed against the possibility that it would limit the oppor-
tunity to explore a genotype–phenotype relationship. We
reiterate that the primary analysis is fixed and independent
of the design: the null hypothesis is that the probability of
response is p0¼ 0.1, and this will only be rejected if the
number of responses is greater than some specified
number r.
Discussion
The two main aims of this study are (a) to identify a best
tolerated dose of Imatinib for patients with PAH and (b) to
establish its efficacy at this dose. An exploratory aim is to
evaluate the response to Imatinib by patient genotype.
The dose range that will be explored, 100mg to 400mg
daily, is based on IMPRES and clinical experience with the
drug outside that study. In IMPRES, patients who were
able to continue Imatinib for six months showed an
improvement in 6MWD and haemodynamic measurements,
but only 47% of patients were able to tolerate the drug at a
dose of 400mg for at least 11 weeks10; and practically all
patients discontinued the drug in the long-term extension.35
Anecdotal reports suggest that lower doses, as low as
100mg daily, used on compassionate grounds are better
tolerated and may still offer patient benefit.
Our decision to opt for a Bayesian CRM in Part 1 means
we can take advantage of prior clinical experience of using
the drug. Integrated with data accrued during the proposed
study, we increase our chances of correctly identifying the
best tolerated dose with fewer patients than otherwise pos-
sible with other dose-finding strategies. It is appreciated that
this has to be balanced against the time delay imposed by
the sequential recruitment of patients at a minimum of four
week intervals, the census point for assessing tolerability for
the statistical model, and the additional time needed to
update the statistical model and assemble the data safety
monitoring team to sign off the dose for each patient. The
decision to use four weeks as the census point is a compro-
mise. Experience from IMPRES suggests that the majority
of patients that discontinue Imatinib do so in the first eight
weeks.10 Leaving a minimum of eight weeks between deci-
sions would prolong Part 1 but as the first patients to be
recruited will be followed up while new patients are
enrolled, we will not lose information from later clinical
presentations of poor tolerability. These later developments
will not inform the statistical model for dose recommenda-
tion in Part 1, but later tolerability and safety concerns will
be factored into the discussion around the choice of dose for
Part 2.
The inclusion of patients with CardioMEMSTM provides
additional opportunities. Here, daily PAP measurements
will be available to provide insight into the haemodynamic
response to the drug. Interindividual differences in clinical
response to Imatinib are well documented, with some
patients benefiting substantially from addition of the drug
to existing therapy.8,18,19 A responder analysis of patients in
IMPRES shows that some patients gained a >60 m increase
in 6MWD and/or showed substantial reductions (>30%) in
PVR.10 In part, this may be due to variability in exposure to
the drug; plasma tough levels at a given dose are influenced
by body weight, haemoglobin concentration and
Fig. 5. Potential design for Part 2 that uses stochastic curtailment.
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concomitant therapies such as sildenafil and endothelin
antagonists.23,36 Detailed steady-state pharmacokinetic
studies in patients with CardioMEMSTM, measuring both
free and total plasma levels, will permit pharmacokinetic:
pharmacodynamic analysis to better understand the need to
individualise dose to optimise plasma levels. The time-
course of response of PAP to Imatinib exposure will also
inform the duration of Part 2, currently set at 24 weeks but
with the option to shorten if patients show a clear response
in a shorter timeframe.
Part 2 of PIPAH builds on experience with the best tol-
erated dose from Part 1. Here, the use of a multi-stage
design, either a two-stage Simon design or a multi-stage
design using stochastic curtailment,33,34 permits an early
decision on futility and/or efficacy. Such designs reduce
the number of participants receiving an inefficacious treat-
ment and allow investigators to consider other treatments
sooner, while increasing the speed with which an efficacious
treatment can be identified and the next phase planned. The
type-I error-rate and power are controlled. While we are
primarily concerned with making a decision regarding
whether or not to continue investigating Imatinib, estima-
tion of the response rate is also of interest. We acknowledge
the possibility of biased estimation when stopping a trial
early and would account for this by using an unbiased esti-
mator. We also acknowledge the possibility of delayed
responses increasing actual sample size compared to
planned sample size. We have considered curtailment
designs with other properties that may be valuable; for
example, permitting early stopping for lack of effect only,
or permitting early stopping only after a certain level of
information is available. All considered, we have opted
for the Simon two-stage design at this point to enable an
exploratory analysis based on genotype; if the study is pos-
itive but stopped early, we would have fewer patients to
conduct the genotype–phenotype analysis.
A pre-defined genotype-response of interest in Part 2
takes advantage of recognised genetic variation associated
with PDGFRB. In two studies of 3301 and 5368 individuals,
respectively, the same sentinel variant (rs2304058) was
detected with an effect on circulating PDGFRB levels;
each minor allele was associated with one standard devia-
tion in plasma PDGFRB levels.27,28 The effect of this
common variant on the circulating proteins levels was inde-
pendent of protein-altering, germ-line variants in
PDGFRB.27 PDGFRB expression is upregulated in lung
tissue from PAH patients12 and may be involved in the
pharmacological effect of Imatinib on pulmonary vascular
tissue; the IC50 of Imatinib for PDGFRB is around 600
nM,37 a concentration exceeded by trough plasma levels
(averaging 700 ng.ml1) in IMPRES.10,23 Patients entering
PIPAH will be genotyped for the rs2304058 cis-pQTL var-
iant. DNA will also be available for additional genotype-
response analysis and these data will be used to inform a
follow-on biomarker-driven study if appropriate. Analysis
of plasma samples taken at baseline and after starting
Imatinib will permit analysis for circulating biomarkers
that might predict response or signal early a likely positive
effect of the drug on PVR.
In summary, we present a protocol to evaluate and posi-
tion Imatinib as a treatment for PAH based on the use of
adaptive designs that offer potential for efficiencies over
more traditional designs. In Part 1, we employ CRM to
assess tolerability and inform a dose for an efficacy study.
In Part 2, we introduce and discuss the merits of Simons two
stage and curtailment designs to enable early stopping for
lack of effect. We anticipate that including some patients
with CardioMEMSTM in Part 1 we will gain some insight
into how to optimise Part 2.
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Appendix 1. Schedule of events
Study period




















Location Clinic Clinic/Home ( ( ( Clinic/Home Clinic/Home Clinic/Home ( ( Clinic/Home ( Clinic/Home
Time (weeks) Before Week 0 Week 0 Week 1 Week 2 Week 3 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week 28g when needed
Assessment window (days) 0–28  3 days  3 days  3 days  3 days  3 days  3 days  3 days  3 days  3 days  3 days  3 days n/a
Inclusion/exclusion criteria X – – – – – – – – – – – –
Written informed consent X – – – – – – – – – – – –
Demographics X – – – – – – – – – – – –
Medical and medication
history
X – – – – – – – – – – – –
Physical examination X X – – – X X X – – X – X
Concomitant medications X X X X X X X X X X X X X
Vital signs X X – – – X X X – – X – X
WHO functional class X – – – – X X X – – X – Xe
Six-minute walk test (6MWT) X X – – – X X X – – X – Xe
Borg dyspnoea index X X – – – X X X – – X – Xe
*Right heart catheterization – Xa,h – – – – – – – – Xa – –
Mouth swab sample X – – – – – – – – – – – –
Haematology blood tests X X – – – X X X – – X – Xe
Clinical chemistry tests (incl.
virology at screening)
Xb X – – – X X X – – X – Xe
Serum pregnancy test Xc Xc – – – Xc Xc Xc – – Xc – –
Home urine pregnancy test – – – – – – – – Xc,d Xc,d – Xc,d –
Home body weight and ankle
swelling self-check
– – X X X – – – X X – X –
Imatinib assay – X – – – X Xi Xi – – X – –
Research blood samples – X – – – X – – – – X – –
Electrocardiogram (ECG) – X – – – X X X – – X – Xe
Echocardiogram X – – – – – – – – – X – Xe
Brain MRI scan Xa – – – – – – – – – – – –
Optional CT head scan Xa,f – – – – – – – – – – – –
Quality of life questionnaire – X – – – X – – – – X – –
Administration of Imatinib – X – – – – – – – – X – –






















































Review of the diary, Imatinib
collection and
reconciliation
Report of adverse events, if
any
– X X X X X X X X X X X X
*Except for patients with an implanted CardioMEMSTM device.
aCan be performed on a separate day 3 days apart from the original visit date, as needed.
bVirology tests apply to this visit only.
cFor women of childbearing potential.
dUrine pregnancy (b-hCG) tests will be performed at home. A telephone call will be performed within 72 hours of the urine test date to enquire about the results.
eIf clinically required.
fA CT head scan will be performed at screening, when MRI is contra-indicated or not tolerated. The brain MRI scan will always be the first choice.
gThe follow-up telephone assessment can be performed after early termination as long as patients are off study drug for 4 weeks (3 days).
hCan be omitted if patient had right heart catheterisation outside the study within a month prior to screening. On this occasion, retrospective catheterisation data (up to one month old) can be used for both
screening and baseline entries.
iSubjects in Part 1 may undergo detailed pharmacokinetic sampling on one of these occasions, if not performed on Week 4.
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